International variation in and factors associated with hospital readmission after myocardial infarction.
暂无分享,去创建一个
Laine Thomas | Paul W Armstrong | Padma Kaul | P. Armstrong | W. Weaver | C. Granger | Manesh R Patel | R. Lopes | J. Hochman | P. Kaul | R. Mehta | K. Pieper | L. Thomas | Christopher B Granger | Judith S Hochman | W Douglas Weaver | Karen S Pieper | R. Kociol | R. Clare | Rajendra H Mehta | Robb D Kociol | Renato D Lopes | Robert Clare | M. Patel | Manesh R Patel | K. S. Pieper | P. Armstrong | R. Mehta | W. Weaver | Christopher B Granger | Renato D. Lopes
[1] D. Chamberlain,et al. Policy for early discharge after acute myocardial infarction. , 1980, British medical journal.
[2] R. Califf,et al. International differences in evolution of early discharge after acute myocardial infarction , 2004, The Lancet.
[3] R. Schröder. Prognostic Impact of Early ST-Segment Resolution in Acute ST-Elevation Myocardial Infarction , 2004, Circulation.
[4] C. Yancy,et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. , 2010, JAMA.
[5] D. Levy,et al. Temporal Trends in Coronary Heart Disease Mortality and Sudden Cardiac Death From 1950 to 1999: The Framingham Heart Study , 2004, Circulation.
[6] David W Baker,et al. Trends in postdischarge mortality and readmissions: has length of stay declined too far? , 2004, Archives of internal medicine.
[7] M S Golden,et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.
[8] S. Normand,et al. Patterns of Hospital Performance in Acute Myocardial Infarction and Heart Failure 30-Day Mortality and Readmission , 2009, Circulation. Cardiovascular quality and outcomes.
[9] G. Anderson,et al. Multinational Comparisons of Health Systems Data, 2008 , 2000 .
[10] P. Armstrong,et al. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. , 2005, American heart journal.
[11] J. Alpert,et al. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction , 2008 .
[12] S. Brener. Insights into the pathophysiology of ST-elevation myocardial infarction. , 2006, American heart journal.
[13] P. Armstrong,et al. A Model for Predicting Mortality in Acute ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Results From the Assessment of Pexelizumab in Acute Myocardial Infarction Trial , 2010, Circulation. Cardiovascular interventions.
[14] J. McMurray,et al. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994 , 1999, Heart.
[15] B. J. Gersh. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000 , 2008 .
[16] Ajai Kumar Jain,et al. PexeLizumab for Acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial , 2007 .
[17] Julia A. Critchley,et al. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000 , 2004 .
[18] M. Simoons,et al. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. , 1997, The New England journal of medicine.
[19] M. Hashemzadeh,et al. Trends in the age adjusted mortality from acute ST segment elevation myocardial infarction in the United States (1988-2004) based on race, gender, infarct location and comorbidities. , 2009, The American journal of cardiology.
[20] H. Krumholz,et al. Association of early follow-up after acute myocardial infarction with higher rates of medication use. , 2008, Archives of internal medicine.
[21] H. Krumholz,et al. All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients. , 2009, Journal of the American College of Cardiology.
[22] M. Desai,et al. Statistical Models and Patient Predictors of Readmission for Acute Myocardial Infarction: A Systematic Review , 2009, Circulation. Cardiovascular quality and outcomes.
[23] A. Jha,et al. The Association Between Hospital Volume and Processes, Outcomes, and Costs of Care for Congestive Heart Failure , 2011, Annals of Internal Medicine.
[24] J. Alpert,et al. Universal definition of myocardial infarction. , 2007, European heart journal.
[25] W. Rogers,et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. , 2000, Journal of the American College of Cardiology.
[26] D. Mozaffarian,et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.